Dr. Kini performs over 1,000 coronary interventions annually (the highest number by a female interventionalist in the United States) with an extremely low complication rate of less than 0.3 percent. In 2011, an official annual report from The Department of Health recognized Dr. Kini as the safest operator among 350 other physicians in the state of New York.
Dr. Annapoorna Kini serves as a Professor of Medicine, Director of Cardiac Catheterization Laboratory and Director of interventional cardiology fellowship at The Mount Sinai Medical Center. Dr. Kini is an international leader in the field of percutaneous coronary intervention and heart valve therapy.
In collaboration with Dr. Sharma, she started the Live Symposium of Complex Coronary and Vascualr Cases in 1998 and has been receiving an astounding success every year. Her achievements are not only limited to serving as the Director of the Annual Live Symposium of Complex Coronary & Vascular Cases at The Mount Sinai Medical Center, one of the most attended and respected meetings in the field of interventional cardiology in the country, but as also being the Director of monthly web conferences on Live Complex Coronary Intervention Cases hosted by the prestigious www.cardiosource.org with a worldwide audience of several thousand physicians.
She has an extensive experience with the techniques of mitral and aortic balloon valvuloplasty, and has been among the first interventional cardiologists in the country to use transcutaneous aortic valve implantation procedure in the treatment of unoperable patients with critical aortic stenosis.
She is co-author (with Dr. Samin K. Sharma) of Coronary artherectomy: Contemporary concepts in cardiology and (with Dr. Valentin Fuster) of Definitions of acute coronary syndromes in Hurst's The Heart.
Kini graduated from India's Vivekananda College in 1984. She received her MBBS from Kasturba Medical College in 1991, completing residencies at the University of Wales College of Medicine (in 1996). She completed three fellowships at Mount Sinai Medical Center – in 1997, 2001, and 2002, respectively.
Annapoorna Kini currently resides in New York and is married with two children. One is a freshman at Columbia University, and has expressed interest in becoming an investment banker. In her free time, Kini enjoys racquetball and recreational jazz dancing.
Awards and recognition
- 2011- “Dean's Award for Excellence in ClinicalMedicine”. Mount Sinai Hospital
- 2011-“Rock Star of Science” award from AHA at Grand Hyatt, New York
- 2011- Dean's Award for Excellence in Clinical Medicine at The Mount Sinai Medical Center.
- 1999- Young Investigator Award of American Association of Cardiology of Indian Origin (AAICO).
- 1990- Gold medal for best outgoing student in the Final MBBS ( Mangalore University).
- 1989- Gold medal (First Place) in Internal Medicine (Ophthalmology and Anatomy) from Mangalore University.
Grants and trials
- Chronometric Observations of Lipid CoreContaining Plaques of Interest in Native Coronary Arteries Registry: COLORRegistry. Sponsored by Infra ReDx Inc.
- A randomized, double-blind, triple-dummy trialto compare the efficacy of otamixaban with Unfractionated Heparin +eptifibatide, in patients with Unstable angina/Non ST segment ElevationMyocardial infarction scheduled to undergo and early invasive strategy.EKG-Glove. Sponsored by Ineed MD.
- YELLOW Trial: The study will assess theregression of yellow plaque content of the lipid pool after aggressive lipidtherapy by utilizing NIR spectroscopy. Intense statin therapy usingRosuvastatin 10-40 mg will be compared to the standard statin therapy.Sponsored by MSSM.
- Expert CTO Trial: A prospective, multi-center, single-arm study toestablish the safety and efficacy of XIENCE V Everolimus Eluting CoronaryStent, XIENCE nano Everolimus Eluting Coronary Stent, HI-TORQUE PROGRESSCoronary Guide Wires, HI-TORQUE PILOT Coronary Guide Wires and MINI-TREKCoronary Dilatation Catheter in patients undergoing elective percutaneousrevascularization of native chronic total coronary occlusions. Sponsored by Abbott Vascular.
- Excel Trail: Evaluationof XIENCE PRIME™ or XIENCE V®versus Coronary Artery Bypass Surgeryfor Effectiveness of Left MainRevascularization. Role: Sponsored by Abbott Vascular.
- CoreValve®U.S. Pivotal Trial (High Risk Surgical Subjects). Sponsored by Medtronic.
- Tryton SB trial: AProspective, Single Blind, Randomized Controlled Study to Evaluate the SafetyAnd Effectiveness of the Tryton Side Branch Stent™ used in Conjunction with aDrug-Eluting Stent Compared to Side Branch Balloon Angioplasty in Conjunctionwith a Drug-Eluting Stent in the Treatment of de novo BifurcationLesions Involving the Main Branch and Side Branch within the Native CoronaryCirculation. Sponsored by Tryton Medical Inc.
- ABSORB 3: Clinical Evaluation of the ABSORB™ Bioresorbable Vascular Scaffold (BVS)in the Treatment of Subjects with de novo Native Coronary ArteryLesions. Sponsored by Abbott Vascular.
Books, Chapters and Invited contributions
- Kim M, KiniA, Fuster V. Definitions of acute coronarysyndromes: Hurst’s The Heart 11th edition; Chapter 48, 1215-1222, todate since 2004.
- Sharma S, Kini A. Coronary atherectomy. Contemporary concepts incardiology, edited by Richard Gorlin, George Dangas, Pavlos Toutouzas, MKonstadoulakis, Kluwer academic publisher Inc; 463-478, 1999.
- Kini A. Coronary angiography, lesionclassification and severity assessment. Cardiology Clinics 24(2):153-62, 2006.
- Sharma S, Kini A. Coronary bifurcation lesions.Cardiology Clinics 24(2):233-46, 2006.
- Sharma S, Bagga R, Kini A. Debulking approachesprior to stenting in interventional cardiology. Edited by Stephen Ellis and David Holmes, LippincottWilliams & Wilkins 116-124, 2006.
- Sarkar K, Kini A, Sharma S. Treatment ofthrombotic lesions in STEMI: The role of thrombectomy devices. Textbook on newapproaches for STEMI interventions by Sameer Mehta Editor 2008.
- Sharma S, Kini A. Preface. Cardiol Clin.2010.
- Kini A, Baber U,Kovacic JC. Changes in Plaque Lipid Content After Short-Term, Intensive VersusStandard Statin Therapy: The YELLOW Trial. J Am Coll Cardiol 2013, May 1.
- Kini A,Muntner P, Moreno P, Mann D, Krishnan P, Kim M, Rafael O, Farkouh M, SharmaS. Relation ofHigh-Density Lipoprotein Cholesterol to Mortality After Percutaneous CoronaryInterventions in Patients With Low-Density Lipoprotein <70 mg/dL. Am J Cardiol, 103(3):350-354, 2009.
- Kini A, Rafael O, Sarkar K, Rajdev S, Jakkula M, MaresA, Kaplish D, Krishnan P, Kim M, Sharma S. Changing Outcomes and TreatmentStrategies for Wire Induced Coronary Perforations in the Era of BivalirudinUse. Cathet Cardiovasc Intervent 74(5): 700-7, 2009.
- Kini A, ChenV, Krishnan P, Kim M, Suleman J, Mares A, Moreno P, Sharma S. Bolus-only vs.Bolus + infusion of Glycoprotein Iib/IIIa inhibitors during percutaneouscoronary intervention. Am Heart J 156(3):513-9, 2008.
- Kini A, Kim M,Moreno P, Krishnan P, Ivan O, Sharma S. Comparison of coronary flow reserve andfractional flow reserve in patients with versus without diabetes mellitus andhaving elective percutaneous coronary intervention and abciximab therapy (fromthe PRECIDT trial). Am J Cardiol 101(6):796-800, 2008.
- Kini A, Moreno P, Steinheimer A, Prattipati M,Suleman J, Kim M, Sharma S. Effectiveness of the Stent Pull-Back Technique forNon-Aorto Ostial Coronary Narrowings. Am J Cardiol 96:1123-1128, 2005.
- Kini A, Lee P, Mitre C, Kim M, Kamran M, DuffyM, Marmur J, Sharma S. Prediction of outcome after percutaneous coronaryintervention for acute coronary syndrome. Am J Med 115:708, 2003.
- Kini A,Lee P, Mitre C, Duffy M, Sharma S. Post-procedure chest painfollowing coronary stenting: Implications on clinical restenosis. J Am CollCardiol 41:33, 2003.
- Kini A,Mitre C, Kamran M, Kim M, Duffy M, Marmur J, Sharma S. Changing trends and predictors of radiographic contrastnephropathy after percutaneous coronary intervention with use of fenoldopam. AmJ Cardiol 89:999, 2002.
- Kini A,Richard M, Suleman J, Perez N, Lee P, Kamran M, Marmur JD, Sharma SK.Effectiveness of tirofiban, eptifibatide, abciximab in minimizing myocardialnecrosis during percutaneous coronary intervention (TEAM pilot study). Am JCardiol 90:526, 2002.
- Kini A,Mitre C, Kim M, Kamran M, Reich D, Sharma S. A protocol for prevention ofradiographic contrast nephropathy during percutaneous coronary intervention:effect of selective dopamine receptor agonist fenoldopam. Cathet CardiovascIntervent 55:159, 2002.
- Kini A,Reich D, Mitre C, Sharma S. A risk stratification scheme for selection of aglycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention basedon clinical and angiographic criteria. Am J Cardiol 88:1287, 2001.
- Kini A,Reich D, Marmur J, Sharma S. Does abciximab limit the CK-MB elevation afterrotational atherectomy of type B2 lesions? Results of the RotaReoPro randomized trial. Am Heart J 142:965, 2001.
- Sharma S, Kini A,Marmur J, Fuster V. Cardio-protective effect of prior beta-blocker therapy inreducing CK-MB elevation after coronary intervention: Benefit is extended toimprovement in intermediate term survival. Circulation 102:166, 2000.
- Kini A,Marmur J, Dangas G, Santiago M, Choudhary S, Sharma S. Angiographic patterns ofin-stent restenosis and implications on subsequent revascularization. CathetCardiovasc Intervent 49:23, 2000.
- Kini A, MarmurJ, Kini S, Dangas G, Wallenstein S,Cocke T, Brown E, Ambrose J, Sharma S. Creatine kinase-MB elevation aftercoronary intervention correlates with diffuse atherosclerosis and low-to-mediumlevel elevation has a benign clinical course: Implication for early dischargeafter coronary intervention. J Am Coll Cardiol 34:663, 1999.
- Kini A, KiniS, Marmur J, Bertea T, Dangas G, Cocke T, Sharma S. Incidence and mechanism ofcreatine kinase-MB enzyme elevation after coronary intervention with differentdevices. Cathet Cardiovasc Intervent 48:123, 1999.
- Kini A, Marmur J, Duvvuri S, Choudhary S, Dangas G, Sharma S. Rotational Atherectomy:Improved procedural outcome with evolution of technique and equipment - Singlecenter results of 1000 patients. Cathet Cardiovasc Intervent 46:305,1999.